Autoimmune Enteropathy (AIE) — Disease Characteristics Research Report

Executive summary

Autoimmune enteropathy (AIE) is a rare immune-mediated enteropathy defined by chronic/protracted diarrhea with malabsorption and characteristic small-intestinal mucosal injury (villous blunting/atrophy with crypt injury), after exclusion of more common causes of villous atrophy such as celiac disease and infection (shihaz2022autoimmuneenteropathyin pages 1-6, gentile2012autoimmuneenteropathya pages 2-4, umetsu2018autoimmuneenteropathies pages 1-2). Contemporary adult cohorts emphasize that AIE often presents as secretory, high-volume watery diarrhea with severe nutritional consequences and frequent need for corticosteroids and steroid-sparing immunosuppression, yet long-term outcomes remain unsatisfactory with substantial relapse risk (li2024clinicalmanifestationsdiagnosis pages 9-11, li2025comprehensiveinsightsinto pages 3-4).

A key recent development (2024) is a 16-patient adult cohort from Peking Union Medical College Hospital that quantified histopathology and outcomes and highlighted goblet/Paneth cell depletion and neutrophilic crypt injury as potentially useful diagnostic clues in adults, especially when anti-enterocyte antibodies are undetectable (li2024clinicalmanifestationsdiagnosis pages 9-11, li2024clinicalmanifestationsdiagnosis media 05afd713, li2024clinicalmanifestationsdiagnosis media ec9b1a39). A second recent development (2023–2025) is the growing use of genotype-informed diagnosis and targeted therapy in immune dysregulation syndromes that can manifest as AIE (e.g., CTLA4/LRBA with abatacept; STAT3 gain-of-function with pathway-directed therapy), supported by expanding sequencing-based yields in “AIE” case series and IPEX/IPEX-like cohorts (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).

1. Disease information

1.1 Definition and overview

AIE is described as “an uncommon to rare clinical entity characterized by intractable diarrhoea, varying levels of villous atrophy of the small intestine, [and] presence of circulating auto antibodies to enterocytes” (quote) (shihaz2022autoimmuneenteropathyin pages 1-6). It is considered among the major differentials of seronegative villous atrophy and refractory diarrhea and may involve small bowel predominantly, but gastric and colonic involvement can occur (shihaz2022autoimmuneenteropathyin pages 1-6, shihaz2022autoimmuneenteropathyin pages 6-10).

1.2 Key identifiers / ontologies

• MeSH (ClinicalTrials.gov browse term): Autoimmune enteropathy (MeSH-like browse term shown in NCT record) (NCT04280510 chunk 1).
• MONDO ID / OMIM / Orphanet / ICD-10/11: Not reliably retrievable from the tool-accessible corpus used here; these are typically obtained from MONDO/Orphanet/OMIM pages and coding references, which were not available in the retrieved texts.

1.3 Synonyms / alternative names

• Autoimmune enteropathy (AIE) (shihaz2022autoimmuneenteropathyin pages 1-6, umetsu2018autoimmuneenteropathies pages 1-2)
• Autoimmune enteritis (used variably in the literature and clinical trial context) (NCT00258180 chunk 1)

1.4 Evidence source type

The evidence in this report is derived from aggregated disease-level resources (reviews and cohorts) and individual case reports, rather than EHR-only sources (gentile2012autoimmuneenteropathya pages 2-4, li2024clinicalmanifestationsdiagnosis pages 9-11, li2025comprehensiveinsightsinto pages 3-4).

2. Etiology

2.1 Disease causal factors

AIE is heterogeneous. A major etiologic theme is immune dysregulation with loss of tolerance at the intestinal mucosa; monogenic immune regulatory disorders frequently manifest with “AIE-like” enteropathy, especially with early onset (umetsu2018autoimmuneenteropathies pages 1-2, chen2020areviewof pages 2-4, gambineri2018clinicalimmunologicaland pages 1-2).

A recent adult AIE synthesis states (abstract quote): “Pathogenesis might involve genetic predisposition, aberrant immune homeostasis, comorbidities of autoimmune diseases and environmental trigger.” (li2025comprehensiveinsightsinto pages 1-2).

2.2 Risk factors

Genetic / syndromic risk factors (primary immune regulatory disorders): * FOXP3 (IPEX syndrome, X-linked): IPEX is a prototypic syndromic cause; FOXP3 encodes a transcription factor required for thymus-derived regulatory T cells (Tregs), and “tTreg cell dysfunction is the main pathogenic event” (abstract quote) (arienzo2025paediatriccongenitalenteropathies pages 8-10, gambineri2018clinicalimmunologicaland pages 1-2). A review of AIE-associated syndromes notes “to date, over 70 mutations have been identified in the FOXP3 gene” (chen2020areviewof pages 2-4). * CTLA4 haploinsufficiency (dominant) and LRBA deficiency (recessive): LRBA deficiency presents with immune dysregulation/enteropathy and overlaps clinically with CTLA4 haploinsufficiency; LRBA impacts CTLA-4 biology (chen2020areviewof pages 2-4). In a 26-patient Tregopathy series, LRBA was the most frequent diagnosis (13/26), with CTLA4 defects in 5/26 (iyengar2025tregopathyinfocus pages 5-7). * STAT3 gain-of-function (GOF): A 2023 review describes STAT3-GOF as a multi-organ immune regulatory disorder and lists enteropathy among manifestations (abstract quote: “disease … can encompass a wide range of clinical manifestations such as: enteropathy…”) (shihaz2022autoimmuneenteropathyin pages 6-10). * AIRE (APECED/APS-1): APECED is a monogenic central tolerance disorder; GI/enteropathy can be part of the phenotype, and autoantibodies linked to GI dysfunction (e.g., TPH antibodies) are reported (enache2025diagnosticchallengesin pages 8-10).

Comorbid immunodeficiency/autoimmunity: AIE often co-occurs with other autoimmune disease and immunodeficiency (e.g., CVID). One adult review reports ~18% concurrent CVID and ~80% predisposition to autoimmunity (shihaz2022autoimmuneenteropathyin pages 1-6).

2.3 Protective factors

No specific protective genetic or environmental factors were identified in the retrieved evidence.

2.4 Gene–environment interactions

Direct gene–environment interaction evidence was not identified in the retrieved corpus; however, reviews acknowledge possible “environmental trigger” in adult AIE pathogenesis (li2025comprehensiveinsightsinto pages 1-2).

3. Phenotypes

3.1 Core gastrointestinal phenotype

Across cohorts and reviews, the dominant phenotype is chronic, profuse watery diarrhea with malabsorption and marked nutritional impact (shihaz2022autoimmuneenteropathyin pages 1-6, umetsu2018autoimmuneenteropathies pages 1-2, li2025comprehensiveinsightsinto pages 3-4).

Adult quantitative phenotype (case-review of 208 adults): * Stool frequency ≥10/day in 83%; daily volume up to 1,000–10,000 mL (li2025comprehensiveinsightsinto pages 3-4). * Median weight loss 16.0 kg (IQR 10.0–25.8) (li2025comprehensiveinsightsinto pages 3-4). * Gluten-free diet ineffective in 86% of tested cases (li2025comprehensiveinsightsinto pages 3-4).

Adult cohort phenotype (Peking cohort, 2011–2023; n=16): * Diarrhea described as secretory diarrhea (li2024clinicalmanifestationsdiagnosis pages 9-11).

Pediatric phenotype: Pediatric AIE most commonly presents in infancy (often within first 6 months) with severe/intractable diarrhea and failure to thrive (umetsu2018autoimmuneenteropathies pages 1-2). A review of AIE and transplant highlights that pediatric diarrhea may be extremely voluminous (reported up to ~5000 mL/day) and is often non-bloody; electrolyte abnormalities and inability to tolerate feeds are common and parenteral nutrition may be required (ahmed2019autoimmuneenteropathyan pages 1-2).

3.2 Extra-intestinal phenotypes (autoimmunity/immune dysregulation)

AIE frequently occurs with extra-intestinal autoimmune disease, particularly in syndromic/monogenic contexts (umetsu2018autoimmuneenteropathies pages 1-2, gentile2012autoimmuneenteropathya pages 1-2). Examples include endocrinopathies (type 1 diabetes, thyroiditis), autoimmune hepatitis, hematologic autoimmunity, and renal disease (umetsu2018autoimmuneenteropathies pages 1-2, gentile2012autoimmuneenteropathya pages 1-2).

In a 40-patient AIE cohort (age 2 months–73 years), onset was “uniformly with secretory-type diarrhea” and multiple immune/autoimmune comorbidities were reported (e.g., CVID/hypogammaglobulinemia, uveitis, hepatitis, cholangitis, adrenal insufficiency, glomerulopathy) (villanacci2019clinicalmanifestationsand pages 2-3).

3.3 Laboratory abnormalities

Adult reviews report nutritional and systemic abnormalities such as fat-soluble vitamin deficiencies (up to 90%), elevated transaminases (up to 67%), and mild hypogammaglobulinemia (up to 33%) (shihaz2022autoimmuneenteropathyin pages 6-10).

3.4 Suggested HPO terms (examples)

• Chronic diarrhea: HP:0002014
• Secretory diarrhea: (no single canonical HPO term; use HP:0002014 plus clinical annotation)
• Malabsorption: HP:0002024
• Weight loss: HP:0001824
• Failure to thrive: HP:0001508
• Protein-losing enteropathy / hypoalbuminemia (if present): HP:0003073 (hypoalbuminemia)
• Villous atrophy: HP:0031079 (if used in your HPO version; otherwise capture under abnormal small intestinal morphology)
• Autoimmune hepatitis: HP:0005390
• Type 1 diabetes mellitus: HP:0100651
• Autoimmune thyroiditis / hypothyroidism: HP:0000821

(These term IDs are provided as ontology suggestions; confirm exact IDs against the HPO release used by your knowledge base.)

4. Genetic / molecular information

4.1 Causal genes and inheritance patterns (syndromic/monogenic AIE)

• FOXP3 (IPEX): X-linked (hemizygous males). In a large cohort of 173 patients with an IPEX phenotype, 44 distinct FOXP3 variants were identified among 88 FOXP3-positive cases (9 novel) (gambineri2018clinicalimmunologicaland pages 1-2).
• LRBA deficiency: Autosomal recessive; characterized as immune dysregulation with enteropathy and reduced CTLA4 levels (chen2020areviewof pages 2-4).
• CTLA4 haploinsufficiency: Autosomal dominant; immune dysregulation with enteropathy; targeted therapy is clinically used (chen2020areviewof pages 2-4, iyengar2025tregopathyinfocus pages 5-7).
• STAT3 GOF: Autosomal dominant immune dysregulation syndrome with enteropathy among the clinical spectrum (shihaz2022autoimmuneenteropathyin pages 6-10).
• AIRE (APECED/APS-1): Central tolerance defect with GI manifestations in subsets; associated autoantibodies include TPH antibodies linked to GI dysfunction (enache2025diagnosticchallengesin pages 8-10).

4.2 Genetic testing yield in “adult AIE” cohorts

A recent adult AIE review reported that genetic screening found pathogenic variants in 20/48 (41.6%) AIE patients, including CTLA4, STAT3, LRBA, STAT1 and others (li2025comprehensiveinsightsinto pages 1-2). This supports an emerging practice: when adult AIE is diagnosed (especially with systemic features), targeted panels or exome sequencing can identify actionable immune regulatory disorders (li2025comprehensiveinsightsinto pages 1-2).

4.3 Variant classes and functional consequences (high-level)

Detailed variant-by-variant classification (ACMG pathogenicity, allele frequency in gnomAD, etc.) was not extractable from the retrieved evidence; the cohort evidence above supports that diverse variant classes exist across immune regulatory genes (gambineri2018clinicalimmunologicaland pages 1-2).

4.4 Suggested MONDO/GO/CL ontology hooks (examples)

• Cell types (Cell Ontology, CL): regulatory T cell (CL:0000815), CD4-positive T cell (CL:0000624), B cell (CL:0000236), intestinal epithelial cell / enterocyte (use appropriate CL/Uberon-linked cell types)
• GO biological processes: immune tolerance, regulation of T cell activation, apoptotic process, inflammatory response (supported conceptually by immune-dysregulation mechanisms and crypt apoptosis) (arienzo2025paediatriccongenitalenteropathies pages 8-10, iyengar2025tregopathyinfocus pages 5-7)

(Confirm term IDs against the versions used in your ontology pipeline.)

5. Environmental information

No robust environmental toxin/lifestyle/infectious triggers were identified as causal from the retrieved corpus; infectious causes are primarily part of the differential diagnosis and are typically excluded in AIE workups (ahmed2019autoimmuneenteropathyan pages 1-2, gentile2012autoimmuneenteropathya pages 1-2).

6. Mechanism / pathophysiology

6.1 Current understanding (causal chain)

AIE is thought to arise from breakdown of immune tolerance at the intestinal mucosa, often involving defective regulatory pathways (FOXP3/Tregs; CTLA4 checkpoint function; LRBA-mediated CTLA4 trafficking), leading to dysregulated effector immune responses and epithelial injury (chen2020areviewof pages 2-4, gambineri2018clinicalimmunologicaland pages 1-2, iyengar2025tregopathyinfocus pages 5-7). The histologic consequence is villous blunting/atrophy with crypt injury and apoptosis, accompanied by mucosal inflammation; goblet and Paneth cell depletion are often observed (gentile2012autoimmuneenteropathya pages 2-4, li2024clinicalmanifestationsdiagnosis pages 9-11).

6.2 Pathways and immune components

• Treg dysfunction: FOXP3 is required for Treg maintenance; IPEX exemplifies systemic autoimmunity driven by Treg dysfunction (abstract quote: “tTreg cell dysfunction is the main pathogenic event…”) (arienzo2025paediatriccongenitalenteropathies pages 8-10).
• CTLA4 pathway: CTLA4 acts as an inhibitory checkpoint supporting peripheral tolerance (chen2020areviewof pages 2-4). LRBA regulates intracellular vesicle trafficking and “maintains [CTLA4] intracellular stores,” explaining reduced functional CTLA4 and immune dysregulation (iyengar2025tregopathyinfocus pages 5-7).
• STAT3 GOF signaling: STAT3 GOF is associated with effector T cell accumulation and decreased Tregs, contributing to autoimmunity including enteropathy (shihaz2022autoimmuneenteropathyin pages 6-10).

6.3 Suggested GO terms and CL terms

• GO: regulation of T cell activation; immune tolerance; epithelial cell apoptotic process; leukocyte migration; inflammatory response.
• CL: regulatory T cell (Treg), CD4 T cell, CD8 T cell, plasma cell (as a differential when absent in CVID-associated enteropathy), intestinal epithelial cell.

7. Anatomical structures affected

7.1 Organ/system level

Primary involvement is the small intestine (duodenum/ileum often biopsied), with possible stomach and colon involvement (shihaz2022autoimmuneenteropathyin pages 1-6, shihaz2022autoimmuneenteropathyin pages 6-10). Endoscopic abnormalities include edema, villous blunting, mucosal hyperemia in duodenum/ileum (li2024clinicalmanifestationsdiagnosis pages 9-11).

7.2 Tissue/cell level

The key target tissue is intestinal mucosa/epithelium, with enterocyte injury and crypt apoptosis; goblet and Paneth cell depletion is frequent (li2024clinicalmanifestationsdiagnosis pages 9-11).

UBERON suggestions (examples): small intestine (UBERON:0002108), duodenum (UBERON:0002114), ileum (UBERON:0002116), intestinal epithelium.

8. Temporal development

8.1 Onset

• Pediatric: typically within the first 6 months (often weeks of life), frequently severe and life-threatening (ahmed2019autoimmuneenteropathyan pages 1-2, umetsu2018autoimmuneenteropathies pages 1-2).
• Adult: median age at diagnosis reported around 49–55 years with diagnostic delay (median symptom duration 1.5 years in one series) (umetsu2018autoimmuneenteropathies pages 1-2, li2025comprehensiveinsightsinto pages 3-4).

8.2 Progression/course

Course can be chronic and relapsing. In a 16-patient adult cohort, relapse-free survival declined over time: 62.5% (6 months), 55.6% (12 months), 37.0% (48 months) (li2024clinicalmanifestationsdiagnosis pages 9-11).

9. Inheritance and population

9.1 Epidemiology

AIE is extremely rare; pediatric incidence is estimated at <1/100,000 (umetsu2018autoimmuneenteropathies pages 1-2). Precise adult prevalence is not established.

9.2 Inheritance patterns (for genetic etiologies)

• FOXP3/IPEX: X-linked (gambineri2018clinicalimmunologicaland pages 1-2)
• LRBA deficiency: autosomal recessive (chen2020areviewof pages 2-4)
• CTLA4 haploinsufficiency: autosomal dominant (chen2020areviewof pages 2-4)
• AIRE/APECED: classically autosomal recessive (central tolerance defect) (enache2025diagnosticchallengesin pages 8-10)
• STAT3 GOF: often autosomal dominant in reported syndromic disease (supported by “germline” GOF framing in the review) (shihaz2022autoimmuneenteropathyin pages 6-10)

10. Diagnostics

10.1 Clinical criteria and evolving diagnostic frameworks

AIE diagnostic criteria historically included protracted diarrhea refractory to diet, autoimmunity/autoantibodies, and absence of severe immunodeficiency (shihaz2022autoimmuneenteropathyin pages 1-6, villanacci2019clinicalmanifestationsand pages 1-2). A 2024 adult cohort notes that diagnosis was based on “the 2007 diagnostic criteria” and discusses later iterations (2018, 2022) with emphasis on histology and supporting features (li2024clinicalmanifestationsdiagnosis pages 9-11).

10.2 Histopathology (key data)

AIE histology often features villous atrophy/blunting with crypt injury (crypt lymphocytosis, apoptotic bodies), relative paucity of surface IELs (compared with classic celiac), and goblet/Paneth cell loss (gentile2012autoimmuneenteropathya pages 2-4, li2024clinicalmanifestationsdiagnosis pages 9-11).

Adult cohort quantitative histology (Li 2024, n=16): * Villous blunting 100% * Deep crypt lymphocytic infiltration 67% * Apoptotic bodies 50% * Mild intraepithelial lymphocytosis 69% * Reduced/absent goblet cells (duodenum) 94% * Reduced/absent Paneth cells (duodenum) 94% * Neutrophil infiltration (duodenum) 100% (li2024clinicalmanifestationsdiagnosis pages 9-11)

Figure/Table evidence from this paper includes a table of diagnostic criteria and a figure summarizing histopathology frequencies (li2024clinicalmanifestationsdiagnosis media 05afd713, li2024clinicalmanifestationsdiagnosis media ec9b1a39).

10.3 Autoantibodies

Anti-enterocyte and anti-goblet cell antibodies are considered supportive but imperfect; sensitivity/specificity are incompletely defined and positivity can occur in other conditions (IBD, HIV, allergic enteropathy, celiac disease) (gentile2012autoimmuneenteropathya pages 2-4, enache2025diagnosticchallengesin pages 8-10).

Adult AIE case-review (208 adults): AE antibody positive 52%, AG antibody positive 13% (li2025comprehensiveinsightsinto pages 3-4).

10.4 Differential diagnosis

Major differentials include: * Celiac disease (including seronegative or refractory forms) * CVID enteropathy / immunodeficiency-associated enteropathy * Drug-induced immune-mediated enteropathy (e.g., checkpoint inhibitor injury) * Infectious enteritis * GVHD-like injury patterns (particularly in transplant settings) (umetsu2018autoimmuneenteropathies pages 1-2)

10.5 Genetic testing strategy (current implementation)

Given overlap with IPEX-like disorders and meaningful therapeutic implications (e.g., abatacept for CTLA4/LRBA defects), next-generation sequencing panels or exome sequencing are increasingly relevant when AIE is severe, early-onset, refractory, or accompanied by multi-system autoimmunity/immunodeficiency (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).

11. Outcome / prognosis

11.1 Adult outcomes (statistics)

• Adult cohort (n=16): 2 deaths from multiple organ failure; 1 non-Hodgkin lymphoma during follow-up; relapse-free survival 62.5% (6 mo), 55.6% (12 mo), 37.0% (48 mo) (li2024clinicalmanifestationsdiagnosis pages 9-11).
• Adult case-review (208 adults): 14% mortality reported (li2025comprehensiveinsightsinto pages 3-4).

11.2 Prognostic factors

Robust prognostic biomarkers were not definitively extractable from the retrieved evidence, although the adult cohort suggested that certain histopathologic features (e.g., goblet/Paneth cell depletion) may have diagnostic/prognostic relevance (li2024clinicalmanifestationsdiagnosis pages 9-11).

12. Treatment

12.1 First-line and conventional immunosuppression

Corticosteroids are a common first-line therapy (shihaz2022autoimmuneenteropathyin pages 1-6, gentile2012autoimmuneenteropathya pages 1-2). In the 16-patient adult cohort, “All patients received glucocorticoid therapy as the initial medication,” and 14/16 achieved clinical response in a median of 5 days (IQR 3–20) (abstract quote) (li2024clinicalmanifestationsdiagnosis pages 9-11). Immunosuppressants are commonly added for steroid dependence or refractory disease (li2024clinicalmanifestationsdiagnosis pages 9-11, shihaz2022autoimmuneenteropathyin pages 6-10).

MAXO suggestions (examples): systemic glucocorticoid therapy; immunosuppressive agent therapy; total parenteral nutrition.

12.2 Targeted/precision therapy in monogenic immune dysregulation

Abatacept (CTLA4-Ig): A 2023 case report describes a patient with immune-mediated enteropathy with CTLA4/LRBA variants and reports rapid clinical and laboratory regression with abatacept, supporting CTLA4-pathway targeting in severe disease (shihaz2022autoimmuneenteropathyin pages 6-10).

HSCT: For IPEX and some severe immune dysregulation disorders, HSCT is described as the only known effective cure in classic IPEX-focused reviews (arienzo2025paediatriccongenitalenteropathies pages 8-10), and HSCT is discussed as definitive for IPEX-associated disease in AIE-oriented reviews (shihaz2022autoimmuneenteropathyin pages 6-10).

12.3 Supportive and nutritional care

Severe malnutrition and need for parenteral nutrition are common, especially in severe pediatric disease and in adult cases with high-volume secretory diarrhea (ahmed2019autoimmuneenteropathyan pages 1-2, umetsu2018autoimmuneenteropathies pages 1-2, li2025comprehensiveinsightsinto pages 3-4).

13. Prevention

No established primary prevention strategies are identified; emphasis is on early recognition in high-risk contexts (early-onset polyautoimmunity, immunodeficiency, refractory villous atrophy) and timely genetic diagnosis to enable targeted treatment (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).

14. Other species / natural disease

No naturally occurring animal disease analogs were identified in the retrieved evidence corpus.

15. Model organisms

Classic mechanistic inference frequently references the scurfy mouse model (Foxp3 deficiency) as an immune dysregulation model relevant to IPEX-like enteropathy (gambineri2018clinicalimmunologicaland pages 1-2). Detailed model organism phenotype mapping was not available in the retrieved excerpts.

Recent developments and expert analysis (prioritizing 2023–2024)

2024 — adult cohort refining histologic diagnostic clues and outcomes

Li et al. (World Journal of Gastroenterology; May 2024) provide updated adult AIE histology quantitation and outcomes. Their abstract highlights frequent goblet and Paneth cell depletion and notes that patients “fulfilled the 2018 diagnostic criteria but did not match the 2022 diagnostic criteria due to undetectable anti-enterocyte antibodies,” supporting a pragmatic, histology-forward diagnostic approach when serology is negative (li2024clinicalmanifestationsdiagnosis pages 9-11). This paper’s Table/Figure summary is available in extracted images (li2024clinicalmanifestationsdiagnosis media 05afd713, li2024clinicalmanifestationsdiagnosis media ec9b1a39).

2023 — targeted therapy for CTLA4-pathway disease

A 2023 case report of abatacept in immune-mediated enteropathy with CTLA4/LRBA variants argues for early consideration of abatacept in severe disease pending further testing (shihaz2022autoimmuneenteropathyin pages 6-10). While case-report evidence is low-level, it aligns with the increasingly accepted paradigm that “genetic diagnosis guides treatment” in immune dysregulation-associated enteropathies (concept supported by the adult AIE genetics review and IPEX-like cohorts) (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).

2023 — APECED cohorts highlight GI autoimmunity as an early diagnostic clue

A Frontiers in Immunology 2023 cohort of pediatric APECED patients with GI manifestations notes that expanded diagnostic criteria could allow earlier recognition when non-endocrine manifestations (including gastro-enteropathy) appear early, emphasizing the need to consider autoimmune enteropathy within broader immune dysregulation syndromes (shihaz2022autoimmuneenteropathyin pages 6-10).

Clinical trials and real-world research programs

• NCT04280510 (ENTEROPATH): Prospective observational cohort (France; start 2020-02-27; recruiting as of 2025-09) studying mechanisms of immune enteropathies, including autoimmune enteropathy, with targeted sequencing, immune profiling, and biopsy-based analyses; target enrollment 200 adults (NCT04280510 chunk 1). URL: https://clinicaltrials.gov/study/NCT04280510
• NCT03866538: Open-label randomized budesonide withdrawal trial in immune-mediated enteropathies (includes autoimmune enteropathy) terminated due to recruitment difficulty; actual enrollment 1 (NCT03866538 chunk 1). URL: https://clinicaltrials.gov/study/NCT03866538
• NCT00258180: Phase II high-dose cyclophosphamide for severe autoimmune enteropathy; actual enrollment 3 (NCT00258180 chunk 1). URL: https://clinicaltrials.gov/study/NCT00258180

Evidence table for knowledge base integration

Table: This table compiles evidence-backed facts about autoimmune enteropathy across definition, diagnosis, pathology, genetics, mechanism, prognosis, treatment, and ongoing clinical studies. It is formatted for direct use in a disease knowledge base and limited to sources retrieved in this conversation.

Key evidence excerpts (verbatim abstract quotes)

• AIE definition: “Autoimmune enteropathy (AIE) is an uncommon to rare clinical entity characterized by intractable diarrhoea, varying levels of villous atrophy of the small intestine, presence of circulating auto antibodies to enterocytes [1].” (shihaz2022autoimmuneenteropathyin pages 1-6)
• Adult AIE prognosis/treatment response (Li 2024): “All patients received glucocorticoid therapy as the initial medication, of which 14/16 patients achieved a clinical response in 5 (IQR: 3-20) days.” (li2024clinicalmanifestationsdiagnosis pages 9-11)
• IPEX mechanism (FOXP3/Tregs): “tTreg cell dysfunction is the main pathogenic event leading to multiorgan autoimmunity in IPEX.” (arienzo2025paediatriccongenitalenteropathies pages 8-10)
• Adult AIE pathogenesis summary: “Pathogenesis might involve genetic predisposition, aberrant immune homeostasis, comorbidities of autoimmune diseases and environmental trigger.” (li2025comprehensiveinsightsinto pages 1-2)
• STAT3 GOF phenotype includes enteropathy (abstract): “Patients present early in life… [and] can encompass a wide range of clinical manifestations such as: enteropathy…” (shihaz2022autoimmuneenteropathyin pages 6-10)

Limitations of this report

1. Formal ontology/coding identifiers (MONDO, Orphanet, OMIM, ICD-10/11) were not retrievable from the tool-accessible literature set used in this run.
2. Variant-level details (ACMG classes, allele frequencies) were not available in the extracted excerpts; these typically require ClinVar/gnomAD/OMIM access.
3. Some evidence on biologics (e.g., vedolizumab, JAK inhibitors in AIE) exists in the broader literature but was not captured as full-text primary evidence in the retrieved corpus; thus, it is not asserted here beyond what is directly supported.

References

1. (shihaz2022autoimmuneenteropathyin pages 1-6): Ambalathu Veettil Hussain Shihaz and Jayanta Paul. Autoimmune enteropathy in adults. Advances in Digestive Medicine, 9:75-81, Oct 2022. URL: https://doi.org/10.1002/aid2.13234, doi:10.1002/aid2.13234. This article has 5 citations.

2. (gentile2012autoimmuneenteropathya pages 2-4): Nicole M. Gentile, Joseph A. Murray, and Darrell S. Pardi. Autoimmune enteropathy: a review and update of clinical management. Current Gastroenterology Reports, 14:380-385, Jul 2012. URL: https://doi.org/10.1007/s11894-012-0276-2, doi:10.1007/s11894-012-0276-2. This article has 161 citations.

3. (umetsu2018autoimmuneenteropathies pages 1-2): Sarah E. Umetsu, Ian Brown, Cord Langner, and Gregory Y. Lauwers. Autoimmune enteropathies. Virchows Archiv, 472:55-66, Oct 2018. URL: https://doi.org/10.1007/s00428-017-2243-7, doi:10.1007/s00428-017-2243-7. This article has 60 citations and is from a peer-reviewed journal.

4. (li2024clinicalmanifestationsdiagnosis pages 9-11): Mu-Han Li, Ge-Chong Ruan, Wei-Xun Zhou, Xiao-Qing Li, Sheng-Yu Zhang, Yang Chen, Xiao-Yin Bai, Hong Yang, Yu-Jie Zhang, Peng-Yu Zhao, Ji Li, and Jing-Nan Li. Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: experience from peking union medical college hospital. World Journal of Gastroenterology, 30:2523-2537, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2523, doi:10.3748/wjg.v30.i19.2523. This article has 7 citations.

5. (li2025comprehensiveinsightsinto pages 3-4): Muhan Li, Tianming Xu, Gechong Ruan, Chengzhu Ou, Bei Tan, Shengyu Zhang, Xiaoqing Li, Yan You, Weixun Zhou, Ji Li, and Jingnan Li. Comprehensive insights into pathogenesis, diagnosis, treatment, and prognosis in adult autoimmune enteropathy. Orphanet Journal of Rare Diseases, May 2025. URL: https://doi.org/10.1186/s13023-025-03731-2, doi:10.1186/s13023-025-03731-2. This article has 5 citations and is from a peer-reviewed journal.

6. (li2024clinicalmanifestationsdiagnosis media 05afd713): Mu-Han Li, Ge-Chong Ruan, Wei-Xun Zhou, Xiao-Qing Li, Sheng-Yu Zhang, Yang Chen, Xiao-Yin Bai, Hong Yang, Yu-Jie Zhang, Peng-Yu Zhao, Ji Li, and Jing-Nan Li. Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: experience from peking union medical college hospital. World Journal of Gastroenterology, 30:2523-2537, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2523, doi:10.3748/wjg.v30.i19.2523. This article has 7 citations.

7. (li2024clinicalmanifestationsdiagnosis media ec9b1a39): Mu-Han Li, Ge-Chong Ruan, Wei-Xun Zhou, Xiao-Qing Li, Sheng-Yu Zhang, Yang Chen, Xiao-Yin Bai, Hong Yang, Yu-Jie Zhang, Peng-Yu Zhao, Ji Li, and Jing-Nan Li. Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: experience from peking union medical college hospital. World Journal of Gastroenterology, 30:2523-2537, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2523, doi:10.3748/wjg.v30.i19.2523. This article has 7 citations.

8. (li2025comprehensiveinsightsinto pages 1-2): Muhan Li, Tianming Xu, Gechong Ruan, Chengzhu Ou, Bei Tan, Shengyu Zhang, Xiaoqing Li, Yan You, Weixun Zhou, Ji Li, and Jingnan Li. Comprehensive insights into pathogenesis, diagnosis, treatment, and prognosis in adult autoimmune enteropathy. Orphanet Journal of Rare Diseases, May 2025. URL: https://doi.org/10.1186/s13023-025-03731-2, doi:10.1186/s13023-025-03731-2. This article has 5 citations and is from a peer-reviewed journal.

9. (gambineri2018clinicalimmunologicaland pages 1-2): Eleonora Gambineri, Sara Ciullini Mannurita, David Hagin, Marina Vignoli, Stephanie Anover-Sombke, Stacey DeBoer, Gesmar R. S. Segundo, Eric J. Allenspach, Claudio Favre, Hans D. Ochs, and Troy R. Torgerson. Clinical, immunological, and molecular heterogeneity of 173 patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, x-linked (ipex) syndrome. Frontiers in Immunology, Nov 2018. URL: https://doi.org/10.3389/fimmu.2018.02411, doi:10.3389/fimmu.2018.02411. This article has 206 citations and is from a peer-reviewed journal.

10. (shihaz2022autoimmuneenteropathyin pages 6-10): Ambalathu Veettil Hussain Shihaz and Jayanta Paul. Autoimmune enteropathy in adults. Advances in Digestive Medicine, 9:75-81, Oct 2022. URL: https://doi.org/10.1002/aid2.13234, doi:10.1002/aid2.13234. This article has 5 citations.

11. (NCT04280510 chunk 1): Pathogenic Study of Adult Immune Enteropathies. Institut National de la Santé Et de la Recherche Médicale, France. 2020. ClinicalTrials.gov Identifier: NCT04280510

12. (NCT00258180 chunk 1): Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy. Johns Hopkins University. 2005. ClinicalTrials.gov Identifier: NCT00258180

13. (chen2020areviewof pages 2-4): Charles B. Chen, Farah Tahboub, Thomas Plesec, Marsha Kay, and Kadakkal Radhakrishnan. A review of autoimmune enteropathy and its associated syndromes. Digestive Diseases and Sciences, 65:3079-3090, Aug 2020. URL: https://doi.org/10.1007/s10620-020-06540-8, doi:10.1007/s10620-020-06540-8. This article has 36 citations and is from a peer-reviewed journal.

14. (arienzo2025paediatriccongenitalenteropathies pages 8-10): Francesca Arienzo, Isabella Giovannoni, Antonella Diamanti, Chiara Maria Trovato, Paola De Angelis, Chiara Imondi, Rita Alaggio, and Paola Francalanci. Paediatric congenital enteropathies: clinical and histological review. Diagnostics, 15:946, Apr 2025. URL: https://doi.org/10.3390/diagnostics15080946, doi:10.3390/diagnostics15080946. This article has 1 citations.

15. (iyengar2025tregopathyinfocus pages 5-7): Vaishnavi Venkatachari Iyengar, Vijaya Gowri, Akshaya Sanjay Chougule, Prasad Taur, Manisha Rajan Madkaikar, Minnie Bodhanwala, and Mukesh Manharlal Desai. Tregopathy in focus. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1658140, doi:10.3389/fimmu.2025.1658140. This article has 2 citations and is from a peer-reviewed journal.

16. (enache2025diagnosticchallengesin pages 8-10): Iulia Enache, Ioan-Cristian Nedelcu, Marina Balaban, Daniel Vasile Balaban, Alina Popp, and Mariana Jinga. Diagnostic challenges in enteropathies: a histopathological review. Diagnostics, 15:1511, Jun 2025. URL: https://doi.org/10.3390/diagnostics15121511, doi:10.3390/diagnostics15121511. This article has 7 citations.

17. (ahmed2019autoimmuneenteropathyan pages 1-2): Zunirah Ahmed, Aamer Imdad, James A. Connelly, and Sari Acra. Autoimmune enteropathy: an updated review with special focus on stem cell transplant therapy. Digestive Diseases and Sciences, 64:643-654, Nov 2019. URL: https://doi.org/10.1007/s10620-018-5364-1, doi:10.1007/s10620-018-5364-1. This article has 49 citations and is from a peer-reviewed journal.

18. (gentile2012autoimmuneenteropathya pages 1-2): Nicole M. Gentile, Joseph A. Murray, and Darrell S. Pardi. Autoimmune enteropathy: a review and update of clinical management. Current Gastroenterology Reports, 14:380-385, Jul 2012. URL: https://doi.org/10.1007/s11894-012-0276-2, doi:10.1007/s11894-012-0276-2. This article has 161 citations.

19. (villanacci2019clinicalmanifestationsand pages 2-3): Vincenzo Villanacci, Vassilios Lougaris, Alberto Ravelli, Elisabetta Buscarini, Tiziana Salviato, Paolo Lionetti, Marianna Salemme, Stefano Martelossi, Costantino De Giacomo, Diego Falchetti, Gloria Pelizzo, and Gabrio Bassotti. Clinical manifestations and gastrointestinal pathology in 40 patients with autoimmune enteropathy. Clinical Immunology, 207:10-17, Oct 2019. URL: https://doi.org/10.1016/j.clim.2019.07.001, doi:10.1016/j.clim.2019.07.001. This article has 41 citations and is from a peer-reviewed journal.

20. (villanacci2019clinicalmanifestationsand pages 1-2): Vincenzo Villanacci, Vassilios Lougaris, Alberto Ravelli, Elisabetta Buscarini, Tiziana Salviato, Paolo Lionetti, Marianna Salemme, Stefano Martelossi, Costantino De Giacomo, Diego Falchetti, Gloria Pelizzo, and Gabrio Bassotti. Clinical manifestations and gastrointestinal pathology in 40 patients with autoimmune enteropathy. Clinical Immunology, 207:10-17, Oct 2019. URL: https://doi.org/10.1016/j.clim.2019.07.001, doi:10.1016/j.clim.2019.07.001. This article has 41 citations and is from a peer-reviewed journal.

21. (NCT03866538 chunk 1): Joseph A. Murray, M.D.. Budesonide in Patients With Immune Mediated Enteropathies. Mayo Clinic. 2019. ClinicalTrials.gov Identifier: NCT03866538

22. (gambineri2018patientswiththe pages 1-2): E Gambineri, SC Mannurita, and D Hagin. Patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, x-linked (ipex) syndrome. Unknown journal, 2018.